Immutep CSO and CMO, Dr Frederic Triebel said: “We are pleased with the recruitment of patients in theTACTI-002 clinical trial to date. After dosing the first patient in March this year, we already have 32 patientson study. In addition, we are encouraged by the early signals of efficacy seen in the more advanced part A ofthe study that appear to be consistent with the synergistic efficacy seen in combining efti withpembrolizumab in the TACTI-mel clinical trial. We very much look forward to presenting more detailed andmore mature data at the 34th Annual Meeting of SITC in November.”
We should get a good little rally here so far so good.....
Ann: Immutep expands Part A of TACTI-002 due to positive data, page-4
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 311433 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 113721 | 6 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |